Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Medulloblastoma × Digoxin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Pancreatic Neoplasms 2 Melanoma 2 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Prostatic Neoplasms 1 Neoplastic Cells, Circulating 1 Myelodysplastic Syndromes 1 Medulloblastoma 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Pancreatic Cancer 1

Interventions

Cyclophosphamide 20 Etoposide 19 Temozolomide 16 Carboplatin 16 Filgrastim 15 Vincristine 11 Cisplatin 11 Radiotherapy 10 Thiotepa 9 Melphalan 8 Granulocyte Colony-Stimulating Factor 8 etoposide phosphate 7 Lomustine 7 Peripheral Blood Stem Cell Transplantation 6 Radiation 5 Methotrexate 5 Magnetic Resonance Spectroscopy 5 Topotecan 4 Mesna 4 Gemcitabine 4 Busulfan 4 sargramostim 3 gallium Ga 68 dotatate 3 Thalidomide 3 Stem Cell Transplantation 3 Irinotecan 3 Ifosfamide 3 Donepezil 3 Celecoxib 3 Automobiles 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06701812 2026-02-27

Digoxin Medulloblastoma Study

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting

Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡